Traders bought shares of Edwards Lifesciences Corp (NYSE:EW) on weakness during trading hours on Wednesday following insider selling activity. $36.55 million flowed into the stock on the tick-up and $30.59 million flowed out of the stock on the tick-down, for a money net flow of $5.96 million into the stock. Of all equities tracked, Edwards Lifesciences had the 29th highest net in-flow for the day. Edwards Lifesciences traded down ($1.13) for the day and closed at $188.83Specifically, CEO Michael A. Mussallem sold 32,800 shares of the firm’s stock in a transaction that occurred on Tuesday, February 12th. The shares were sold at an average price of $176.90, for a total transaction of $5,802,320.00. Following the completion of the sale, the chief executive officer now directly owns 75,926 shares in the company, valued at $13,431,309.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Catherine M. Szyman sold 700 shares of the firm’s stock in a transaction that occurred on Tuesday, January 15th. The stock was sold at an average price of $155.00, for a total transaction of $108,500.00. Following the sale, the vice president now owns 24,482 shares of the company’s stock, valued at $3,794,710. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 113,554 shares of company stock valued at $19,946,796. 1.84% of the stock is currently owned by corporate insiders.

Several brokerages recently weighed in on EW. Citigroup raised their price objective on shares of Edwards Lifesciences from $118.00 to $119.00 and gave the company a “sell” rating in a research report on Wednesday, January 2nd. BMO Capital Markets raised their price objective on shares of Edwards Lifesciences to $204.00 and gave the company an “outperform” rating in a research report on Friday, March 22nd. Canaccord Genuity raised their price objective on shares of Edwards Lifesciences from $177.00 to $186.00 and gave the company a “positive” rating in a research report on Wednesday, January 16th. Credit Suisse Group began coverage on shares of Edwards Lifesciences in a research report on Monday, December 17th. They set an “outperform” rating and a $188.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their price objective on shares of Edwards Lifesciences from $175.00 to $190.00 and gave the company a “neutral” rating in a research report on Wednesday, March 27th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. Edwards Lifesciences presently has a consensus rating of “Buy” and a consensus price target of $180.71.

The stock has a market capitalization of $39.27 billion, a PE ratio of 40.50, a price-to-earnings-growth ratio of 2.45 and a beta of 0.91. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.92 and a current ratio of 2.61.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $1.17. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. The firm had revenue of $977.70 million for the quarter, compared to the consensus estimate of $973.72 million. During the same quarter in the previous year, the company earned $0.94 earnings per share. Equities analysts predict that Edwards Lifesciences Corp will post 5.21 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of EW. Standard Life Aberdeen plc boosted its stake in shares of Edwards Lifesciences by 8.7% in the 3rd quarter. Standard Life Aberdeen plc now owns 81,459 shares of the medical research company’s stock valued at $14,184,000 after purchasing an additional 6,529 shares in the last quarter. LPL Financial LLC boosted its stake in shares of Edwards Lifesciences by 9.7% in the 3rd quarter. LPL Financial LLC now owns 17,157 shares of the medical research company’s stock valued at $2,987,000 after purchasing an additional 1,515 shares in the last quarter. Bamco Inc. NY boosted its stake in shares of Edwards Lifesciences by 2.7% in the 3rd quarter. Bamco Inc. NY now owns 38,209 shares of the medical research company’s stock valued at $6,652,000 after purchasing an additional 1,008 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Edwards Lifesciences by 474.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 156,342 shares of the medical research company’s stock valued at $27,220,000 after purchasing an additional 129,124 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its stake in shares of Edwards Lifesciences by 14.9% in the 3rd quarter. Pacer Advisors Inc. now owns 11,424 shares of the medical research company’s stock valued at $1,989,000 after purchasing an additional 1,478 shares in the last quarter. Institutional investors own 84.87% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/investors-buy-shares-of-edwards-lifesciences-ew-on-weakness-after-insider-selling/2956135.html.

Edwards Lifesciences Company Profile (NYSE:EW)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: Why do corrections happen?

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.